Conference Calendar - The 33rd International Papillomavirus Conference

Times are stated in CEST (GMT + 2 / UTC + 2)
Every effort has been made to convert the IPVC 2020 scientific program into a fully virtual program. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive program on the virtual conference platform. Please note that some presenters were not able to pre-record their presentations, therefore there are still some sessions with missing presentations.

To view the pre-conference workshops, you need to register for them separately. Please contact: reg_ipvc20@kenes.com
You will then receive an email with instructions on how to login to the workshops’ platform.

Displaying One Session

View

Clinical Science Oral Session

01020 - Oral Session 10: Vaccines Clinical Aspects (ID 83)

Session Type

Clinical Science Oral Session

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY \u003Csmall\u003E(ID 900)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":900,"presentation":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY \u003Csmall\u003E(ID 900)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Partha Basu (France)","photo":""},"playlist":[{"name":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STU","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/C4A004B2.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.vtt"}]},{"name":"IMMUNE RESPONSE TO QUADRIVALENT HPV VACCINE IN WOMEN AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANT: A NONRANDOMIZED CONTROLLED TRIAL \u003Csmall\u003E(ID 604)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":604,"presentation":"IMMUNE RESPONSE TO QUADRIVALENT HPV VACCINE IN WOMEN AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANT: A NONRANDOMIZED CONTROLLED TRIAL \u003Csmall\u003E(ID 604)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Pamela Stratton (United States of America)","photo":""},"playlist":[{"name":"IMMUNE RESPONSE TO QUADRIVALENT HPV VACCINE IN WOMEN AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSP","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Pamela-Str_1920x900.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Pamela-Str_1920x900.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/3D33AD7F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Pamela-Str_1920x900.vtt"}]},{"name":"EXTENDED IMMUNOGENICITY AND EFFICACY OF THE QUADRIVALENT HPV VACCINE IN A COHORT OF WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 257)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":257,"presentation":"EXTENDED IMMUNOGENICITY AND EFFICACY OF THE QUADRIVALENT HPV VACCINE IN A COHORT OF WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 257)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Deborah Money (Canada)","photo":""},"playlist":[{"name":"EXTENDED IMMUNOGENICITY AND EFFICACY OF THE QUADRIVALENT HPV VACCINE IN A COHORT OF WOMEN LIVING WIT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Deborah Money - IPVC20 - Presentation 257.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Deborah Money - IPVC20 - Presentation 257.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/A5982086.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Deborah Money - IPVC20 - Presentation 257.vtt"}]},{"name":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA \u003Csmall\u003E(ID 1088)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1088,"presentation":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA \u003Csmall\u003E(ID 1088)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Marta Del Pino (Spain)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/76.jpg"},"playlist":[{"name":"BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASI","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/34916072.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/1088 BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA.vtt"}]},{"name":"AMC-072: 24-MONTH EFFICACY OF THE QUADRIVALENT HPV VACCINE AGAINST ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN AGED 18-26 YEARS \u003Csmall\u003E(ID 1100)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1100,"presentation":"AMC-072: 24-MONTH EFFICACY OF THE QUADRIVALENT HPV VACCINE AGAINST ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN AGED 18-26 YEARS \u003Csmall\u003E(ID 1100)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Joel M. Palefsky (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/37.jpg"},"playlist":[{"name":"AMC-072: 24-MONTH EFFICACY OF","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation 1,100.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation 1,100.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/57B77CCF.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation 1,100.vtt"}]},{"name":"HPV VACCINATION AFTER CONIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS \u003Csmall\u003E(ID 592)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":592,"presentation":"HPV VACCINATION AFTER CONIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS \u003Csmall\u003E(ID 592)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Matthias Jentschke (Germany)","photo":""},"playlist":[{"name":"HPV VACCINATION AFTER CONIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/P592_S1200_HPV VACCINATION AFTER CONIZATION A SYSTEMATIC REVIEW AND META-ANALYSIS.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/P592_S1200_HPV VACCINATION AFTER CONIZATION A SYSTEMATIC REVIEW AND META-ANALYSIS.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/4EAD776.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/P592_S1200_HPV VACCINATION AFTER CONIZATION A SYSTEMATIC REVIEW AND META-ANALYSIS.vtt"}]},{"name":"SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES \u003Csmall\u003E(ID 1198)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1198,"presentation":"SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES \u003Csmall\u003E(ID 1198)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Zheng Quan Toh (Australia)","photo":""},"playlist":[{"name":"SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDU","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Ryan Toh - IPVC20 - 1198 - SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Ryan Toh - IPVC20 - 1198 - SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/9A4048B9.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Ryan Toh - IPVC20 - 1198 - SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES-0.vtt"}]}]

Oral Session 10: Vaccines Clinical Aspects Hall B

EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY (ID 900)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

12:35 - 12:50

Presenter

Partha Basu (France)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

IMMUNE RESPONSE TO QUADRIVALENT HPV VACCINE IN WOMEN AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANT: A NONRANDOMIZED CONTROLLED TRIAL (ID 604)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

12:50 - 13:02

Presenter

Pamela Stratton (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

EXTENDED IMMUNOGENICITY AND EFFICACY OF THE QUADRIVALENT HPV VACCINE IN A COHORT OF WOMEN LIVING WITH HIV (ID 257)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

13:02 - 13:14

Presenter

Deborah Money (Canada)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

BENEFITS OF HPV VACCINATION AS ADJUVANT TO CERVICAL TREATMENT IN WOMEN WITH INTRAEPITHELIAL NEOPLASIA (ID 1088)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

13:14 - 13:26

Presenter

Marta Del Pino (Spain)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

AMC-072: 24-MONTH EFFICACY OF THE QUADRIVALENT HPV VACCINE AGAINST ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN AGED 18-26 YEARS (ID 1100)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

13:26 - 13:38

Presenter

Joel M. Palefsky (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

HPV VACCINATION AFTER CONIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS (ID 592)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

13:38 - 13:50

Presenter

Matthias Jentschke (Germany)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

SELECTIVE PERSISTENCE OF HPV CROSS-NEUTRALISING ANTIBODIES FOLLOWING REDUCED-DOSE HPV VACCINE SCHEDULES (ID 1198)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

13:50 - 14:02

Presenter

Zheng Quan Toh (Australia)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 10: Vaccines Clinical Aspects Hall B

Online Chat Q&A for this session is called: CLINICAL SCIENCE ORAL SESSION 10: VACCINES CLINICAL ASPECTS. You can join the online chat Q&A and discussions for this session by going back to the Lobby and entering the Networking Lounge. Speakers are encouraged to be online in the chat room at the time this session is stated to end. All times are in CEST. (ID 1783)

Session Date

07/24/2020

Session Time

12:35 - 14:05

Room

Hall B

Session Type

Clinical Science Oral Session

Session Name

Oral Session 10: Vaccines Clinical Aspects

Lecture Time

14:02 - 14:02